Atranorin

Cat. No.:	HY-N2907
CAS No.:	479-20-9
Molecular Formula:	$C_{19}H_{18}O_8$
Molecular Weight:	374.34
Target:	Ras; Endogenous Metabolite
Pathway:	GPCR/G Protein; Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 16.67 mg/mL (44.53 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6714 mL	13.3568 mL	26.7137 mL
	5 mM	0.5343 mL	2.6714 mL	5.3427 mL
	10 mM	0.2671 mL	1.3357 mL	2.6714 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 1.67 mg/mL (4.46 mM); Suspended solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 1.67 mg/mL (4.46 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Atranorin is a lichen secondary metabolite. Atranorin inhibits lung cancer cell motility and tumorigenesis by affecting AP-1, Wnt, and STAT signaling and suppressing RhoGTPase activity[1][2].

IC_{50} & Target

RhoGTPase[1]

REFERENCES

[1]. Studzinska-Sroka E, et al. Atranorin - An Interesting Lichen Secondary Metabolite. Mini Rev Med Chem. 2017;17(17):1633-1645.

[2]. Zhou R, et al. The lichen secondary metabolite atranorin suppresses lung cancer cell motility and tumorigenesis. Sci Rep. 2017 Aug 15;7(1):8136.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA